Prolia and Xgeva denosumab biosimilars guide: 2024–2026 biosimilar wave, osteoporosis vs oncology indications, HCPCS Q-code mapping, preferred-product policies, and switching

Denosumab (Prolia and Xgeva, Amgen) is a RANKL (receptor activator of nuclear factor kappa-B ligand) inhibitor used to prevent bone loss and skeletal-related events across osteoporosis and oncology indications. The combined U.S. franchise exceeds $5 billion annually, making it one of the highest-revenue biologics facing biosimilar competition. As of March 2026, the FDA has approved ten biosimilar pairs referencing Prolia and Xgeva — the densest biosimilar cluster for any reference product.

This creates an unusually complex access landscape: ten biosimilar manufacturers, four interchangeable designations, payer-specific preferred-product hierarchies that differ between osteoporosis and oncology, and two distinct benefit channels (pharmacy for Prolia, medical for Xgeva). This guide covers the full landscape for access, reimbursement, and switching teams.

Short answer

All FDA-approved denosumab biosimilars

Pending: Alvotech/Dr. Reddy's AVT03 (FDA decision expected 2026).

Critical naming convention

Each manufacturer markets the same biosimilar under two brand names — one for the 60 mg osteoporosis dose (Prolia-type) and one for the 120 mg oncology dose (Xgeva-type). For example, Sandoz's denosumab-bbdz is branded Jubbonti (60 mg, Prolia-type) and Wyost (120 mg, Xgeva-type). They share the same BLA and nonproprietary name but have separate NDCs and may route through different benefit channels.

HCPCS Q-code mapping

Billing units: 1 unit = 1 mg. Prolia dose (60 mg) = 60 units. Xgeva dose (120 mg) = 120 units. Administration code: 96372 (SC injection) or 96401 (chemo SC injection for oncology).

JW/JZ modifiers

Medicare requires JW (discarded) and JZ (no discarded drug) modifiers for single-use containers under all denosumab Q-codes and J0897.

Benefit channel routing

The Prolia/Xgeva split creates two distinct benefit channels:

Prolia-type (osteoporosis): pharmacy or medical benefit

• Most commercial plans route the 60 mg dose through pharmacy benefit (specialty pharmacy)
• Medicare Part B covers Prolia under medical benefit when administered in a physician office (buy-and-bill under J0897)
• Medicare Part D may cover the self-administered version through pharmacy benefit
• Prolia biosimilars follow the same routing as the reference product
• BCBS Michigan routes Prolia authorization through NovoLogix (pharmacy)

Xgeva-type (oncology): medical benefit exclusively

• The 120 mg dose is administered by a healthcare provider in an oncology or infusion setting
• Routes through medical benefit (Medicare Part B) as buy-and-bill
• Xgeva biosimilars follow the same medical benefit path
• BCBS Michigan routes Xgeva authorization through AIM ProviderPortal (medical)
• Claims billed with J0897 or the biosimilar-specific Q-code plus the appropriate oncology ICD-10 codes

Payer preferred-product policies (2026)

Payers are rapidly establishing preferred-product hierarchies that differ between osteoporosis and oncology. The preferred status determines step-therapy requirements.

UnitedHealthcare

Effective September 2025 for Medicare Advantage plans: Jubbonti and Wyost replace Prolia and Xgeva as preferred interchangeable biosimilars. Pharmacies may substitute without a new prescription where permitted by state law.

UHC's commercial medical benefit drug policy (effective January 1, 2026) lists HCPCS J0897, Q5136, and Q5157 with diagnosis-specific ICD-10 code lists. Jubbonti, Prolia, and Stoboclo share the osteoporosis ICD-10 range (M80.00–M81.8, C61, C50, Z79.52, Z79.811). Osenvelt, Wyost, and Xgeva share the oncology ICD-10 range (C61, C79.00–C79.51, C41, D47.C, C88, D47.Z8).

Aetna (Medicare Advantage 2026 Part B)

Osteoporosis (Prolia-type) preferred hierarchy:

1. 1st tier: Zoledronic acid (IV bisphosphonate — first-line step therapy)
2. 2nd tier preferred: Jubbonti, Prolia (after trial/failure of zoledronic acid)
3. Non-preferred: Bildyos, Bosaya, Conexxence, Ospomyv, Stoboclo, Enoby, Osvyrti (require trial of preferred products first)

Oncology (Xgeva-type) preferred hierarchy:

1. Preferred: Osenvelt, Wyost
2. Non-preferred: Aukelso, Bilprevda, Bomyntra, Xbryk, Xtrenbo, Xgeva

CVS Caremark (2026 formulary)

• Xgeva (brand) excluded from the national formulary. Osenvelt is the preferred alternative.
• Prolia (brand) remains on formulary; its biosimilars are excluded from the preferred national template.
• Effective April 2026: Ospomyv and Stoboclo added as preferred osteoporosis biosimilars, replacing Prolia on major national commercial formularies.

Blue Cross Blue Shield of Michigan

Effective December 15, 2025: Osenvelt and Stoboclo are the preferred denosumab biosimilars. All other denosumab products (including brand Prolia, brand Xgeva, Jubbonti, Wyost, Conexxence, Bomyntra, Xbryk, etc.) require step therapy through preferred biosimilars first.

Blue Cross NC (2026)

• Preferred: Jubbonti AND Stoboclo (must try and fail both preferred biosimilars before using non-preferred)
• Non-preferred: Prolia, Bosaya, Conexxence, Ospomyv, Bildyos; Xgeva, Aukelso, Bilprevda, Bomyntra, Xbryk
• Non-preferred agents require trial and failure of both preferred biosimilars for the reference product

Mass General Brigham Health Plan

Effective January 1, 2026: Preferred products are Jubbonti, Stoboclo, Osenvelt, and Wyost. Non-preferred products (Prolia, Bildyos, Conexxence, Ospomyv, Bosaya, Xgeva, Bomyntra, Xbryk, Bilprevda) require trial and failure of preferred biosimilars. Combined Prolia and Xgeva policy into a single document.

Priority Health

Bildyos (Prolia biosimilar) and Bilprevda (Xgeva biosimilar) had prior authorization removed effective November 1, 2025, allowing direct dispensing without PA review.

Step therapy and switching rules

Prolia/Xgeva must never be used concurrently

Both products contain the same active ingredient (denosumab) at different doses. Using them simultaneously leads to excessive RANKL inhibition. Prescribing information explicitly warns against concurrent use.

Rebound risk on discontinuation

Stopping denosumab causes a rapid increase in bone turnover markers within 3 months and BMD decline to pretreatment levels within 2 years. Vertebral fractures have been reported 8–16 months after discontinuation, including multiple vertebral fractures. Drug holidays are not recommended. If denosumab is stopped, transition to a bisphosphonate (typically zoledronic acid or oral alendronate) is advised.

Biosimilar switching rules

• Interchangeable biosimilars (Jubbonti/Wyost, Stoboclo/Osenvelt, Conexxence/Bomyntra, Bildyos/Bilprevda, Ospomyv/Xbryk): may be substituted at the pharmacy level without prescriber consultation, subject to state pharmacy practice laws
• Non-interchangeable biosimilars: require a new prescription from the prescriber
• Illinois exception: Step therapy does not apply for HMO Illinois members per IL HB 5395 unless the biosimilar is interchangeable per FDA Purple Book

Payer-mandated switches

Multiple payers now mandate switching from brand to preferred biosimilars:

• UHC Medicare: direct replacement of Prolia with Jubbonti and Xgeva with Wyost
• BCBSM: step therapy through Stoboclo/Osenvelt before any other denosumab product
• BCBS NC: must try and fail both preferred biosimilars (Jubbonti AND Stoboclo) before non-preferred
• Aetna Medicare: zoledronic acid first-line step therapy for osteoporosis; preferred biosimilars second-line

Access teams should prepare for payer-mandated switches by:

1. Identifying all patients currently on brand Prolia or Xgeva
2. Cross-referencing with each plan's preferred biosimilar
3. Verifying interchangeability status and state substitution laws
4. Ensuring the correct Q-code is loaded for billing
5. Documenting any clinical reason the patient cannot switch (rare but may include prior adverse reaction to a specific biosimilar)

WAC pricing landscape

List-price discounts are modest (3–15%), but actual net cost after rebates, discounts, and ASP-based reimbursement is significantly more competitive. ASP data for the biosimilar Q-codes will increasingly drive Medicare Part B reimbursement downward.

ICD-10 coding by indication

Osteoporosis (Prolia-type)

• M80.00–M80.88: Osteoporosis with current pathological fracture
• M81.0–M81.8: Osteoporosis without current pathological fracture
• C61: Malignant neoplasm of prostate (ADT bone loss)
• C50.011–C50.A2: Breast cancer (aromatase inhibitor bone loss)
• Z79.52: Long-term use of systemic steroids (glucocorticoid-induced)
• Z79.811: Long-term use of aromatase inhibitors
• M05.60–M06.9: Rheumatoid arthritis (not covered for Xgeva-type)

Oncology (Xgeva-type)

• C61: Prostate cancer with bone metastases
• C79.51: Secondary malignant neoplasm of bone
• C79.00–C79.19: Secondary neoplasm of kidney/urinary organs
• C41.0–C41.9: Malignant neoplasm of bone (GCTB)
• C88.0–C88.9: Malignant immunoproliferative diseases (multiple myeloma)
• D47.C: Plasma cell neoplasm (multiple myeloma)

Patient support programs

Amgen SupportPlus (Prolia and Xgeva)

• Copay card: eligible commercially insured patients may pay as little as $0 per dose
• Covers deductible, coinsurance, and copayment
• Enrollment at AmgenSupportPlus.com or 1-866-264-2778
• Benefits verification, prior authorization support, appeals assistance

Organon Access Program (Bildyos/Bilprevda)

• Benefits investigation, billing and coding assistance
• Copay assistance for eligible patients
• Prior authorization and appeals support

Other biosimilar manufacturers

Most biosimilar manufacturers offer access programs including benefit verification, PA support, and copay cards. Check the specific manufacturer's HCP access website for current program details.

Key takeaways for access teams

• Ten biosimilar pairs are now FDA-approved — the most crowded biosimilar market for any reference product. Expect continued payer tiering and step-therapy consolidation through 2026.
• Prolia and Xgeva are the same drug at different doses — they must never be used concurrently and route through different benefit channels (pharmacy vs. medical).
• Five pairs carry interchangeability designations (Jubbonti/Wyost, Ospomyv/Xbryk, Stoboclo/Osenvelt, Conexxence/Bomyntra, Bildyos/Bilprevda) — these can be pharmacy-substituted per state law.
• Preferred-product policies are fragmenting by payer: UHC Medicare prefers Jubbonti/Wyost; BCBSM prefers Stoboclo/Osenvelt; BCBS NC prefers Jubbonti AND Stoboclo. Track each plan's hierarchy.
• Brand Prolia is being excluded or stepped-through at CVS Caremark, Aetna Medicare, and multiple BCBS plans. Patients will be switched.
• Rebound fracture risk on denosumab discontinuation is clinically significant — do not stop denosumab without a transition plan to bisphosphonate therapy.
• Teva's Ponlimsi is Prolia-only — it does not carry Xgeva indications, creating a rare asymmetry in the biosimilar landscape.
• Q-codes for newer biosimilars (Q5161, Q5162) are being assigned through 2026 — verify the correct code before billing; newer products may temporarily require J3590 or J9999.

Sources

• FDA. FDA Approves First Interchangeable Biosimilars to Prolia and Xgeva. March 5, 2024. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and
• FDA. Purple Book Database of Licensed Biological Products. https://purplebooksearch.fda.gov
• Biosimilars RR. US Biosimilar Filings and Approvals Tracker. https://biosimilarsrr.com/us-biosimilar-filings
• UnitedHealthcare. Denosumab Commercial Medical Benefit Drug Policy. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/denosumab-prolia-xgeva.pdf
• Aetna. Denosumab Clinical Policy. https://www.aetna.com/cpb/medical/data/800_899/0804.html
• Blue Cross NC. Denosumab Notification. Effective 01/01/2026. https://www.bluecrossnc.com/content/dam/bcbsnc/pdf/providers/policies-guidelines-codes/commercial/um/medical-benefit/notifications/denosumab-prolia-xgeva-notification-1-1-2026.pdf
• CMS. Billing and Coding: Denosumab. Article A52399. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52399
• Health Net. Denosumab Policy. CP.PHAR.58. https://www.healthnet.com/content/dam/centene/policies/pharmacy-policies/phar/CP.PHAR.58.pdf
• Celltrion USA. FDA Interchangeability Designation. https://www.celltrionusa.com/board/newslist/46